Dette reducerede HbA1c- niveauet med 0, 30% efter 24 uger hos patienter, som fik Januvia og glimepirid, og med 0, 60% hos de patienter, der ligeledes fik metformin i tillæg til Januvia og glimepirid.
This reduced HbA1c levels after 24 weeks by 0.30% in patients receiving Januvia and glimepiride, and by 0.60% in the patients who were also taking also taking metformin in addition to Januvia and glimepiride.